TB-500 10mg 10mg/10ml 1 Vial by Swiss Pharma

Usage

1. Reconstitute with bacteriostatic water: Inject 1–2 ml of bacteriostatic water slowly down the inner vial wall using a 23-gauge needle; never shake — gently swirl until the lyophilised cake dissolves fully.
2. Calculate your draw volume: With 1 ml BW added to 10 mg TB-500, each 0.1 ml = 1 mg. Adjust the dilution volume to suit your preferred syringe markings and dose per injection.
3. Select the correct syringe for the Wolverine stack: Use a 29–31 gauge insulin syringe for subcutaneous injections. Draw slowly to avoid air bubbles and confirm the volume against the syringe barrel markings before injecting.
4. Inject at the correct site and depth: Subcutaneous injections into the abdominal pinch fold are standard; rotate sites between each dose. For intramuscular preference, use the lateral deltoid with a 25-gauge, 1-inch needle.
5. Time relative to BPC-157 in the stack: Administer TB-500 on days that are offset by at least 24 hours from your BPC-157 injections; this prevents dose overlap and allows each peptide's distinct pharmacokinetic window to operate independently.
6. Store correctly between doses: Return the reconstituted vial to the refrigerator (2–8 °C) immediately after each draw. Label the vial with the reconstitution date and discard 28 days after opening regardless of remaining volume.

Warnings

Frequently asked questions

Why should I stack BPC-157 with TB-500 rather than using either peptide on its own?

Stacking BPC-157 with TB-500 targets two distinct repair mechanisms simultaneously: BPC-157 recruits fibroblasts and stimulates angiogenesis at the localised injury site, while TB-500 mobilises circulating progenitor cells and reduces systemic inflammation via TNF-α and IL-1β suppression. Research models show each peptide produces measurable recovery effects independently, but the combined protocol addresses both the local tissue defect and the broader inflammatory environment, making the stack more comprehensive than either compound alone.

What does a practical Wolverine stack weekly protocol look like when using Swiss Pharma TB-500 10mg?

A standard Wolverine protocol runs 8–12 weeks. During the loading phase (weeks 1–4), TB-500 is dosed at 5–10 mg twice weekly, with BPC-157 dosed at 250–500 µg once or twice daily. TB-500 injections are offset by 24–48 hours from BPC-157 injections to respect each peptide's different half-life. In the maintenance phase (weeks 5–12), TB-500 drops to once weekly at 2.5–5 mg. One 10 mg Swiss Pharma vial covers approximately 1–2 weeks of the loading phase.

Which injury types respond best to the BPC-157 and TB-500 combination stack?

Tendon and ligament injuries — particularly rotator cuff tears, Achilles tendinopathy, and patellar tendinitis — are the most commonly cited targets in peptide-recovery literature. Joint cartilage degradation and muscle-fascia tears also appear in preclinical models as responsive indications. The combination is especially relevant where both localised structural damage and diffuse inflammation are present, which is typical of overuse injuries in strength athletes, since BPC-157 addresses the structural repair while TB-500 handles the inflammatory component.

How do I reconstitute and store the Swiss Pharma TB-500 10mg vial, and how long does it remain viable after opening?

Reconstitute the lyophilised powder by injecting bacteriostatic water (BW) slowly down the vial wall — typically 1–2 ml BW to achieve your target concentration — without agitating the vial. Once reconstituted, store the vial at 2–8 °C (refrigerated, not frozen) and use within 28 days. Lyophilised, unreconstituted vials should be kept below 25 °C, away from light and moisture. Always inspect the solution for particulates or discolouration before drawing a dose.

What syringe type and injection technique is recommended when dosing TB-500 from a 10ml vial?

A 29–31 gauge insulin syringe (0.3–1 ml capacity) is the standard choice for subcutaneous TB-500 administration, allowing precise volume measurement from the 10 ml vial. Draw the calculated volume slowly to avoid frothing, then inject subcutaneously into the abdominal pinch fold or the flank, rotating sites between doses. For intramuscular administration, a 25–27 gauge, 1-inch needle is appropriate. Wipe the vial septum with a 70 % isopropyl alcohol swab before every draw. (2) angle_used

Manufacturer

Swiss Pharma's quality-control pipeline for the TB-500 10mg/10ml injectable vial is anchored to a dual-verification requirement that applies to each individual production lot — not to the product class as a whole. The first analytical gate is reversed-phase HPLC quantification: the TB-500 active peptide concentration in each batch is measured against a certified reference standard, confirming that actual vial content falls within the declared 10 mg specification tolerance before any release decision is made. The second gate is LAL (Limulus Amebocyte Lysate) endotoxin testing of the same lot, which establishes that the sterile solution complies with injectable-grade bacterial endotoxin limits — a non-negotiable requirement for any peptide intended for subcutaneous or intramuscular administration. Both verification results are recorded as lot-specific documentation and must be complete and on file before that batch enters the distribution chain. This framework — distinct from supplier certificates of analysis and independent of the peptide's specific mechanism of action — is the same standard Swiss Pharma applies uniformly across its injectable peptide portfolio, ensuring that the HPLC-Verified badge on this TB-500 vial reflects a concrete, documented analytical event rather than a generic quality claim.